Bio View Altman Z-Score
The Altman Z-Score of Bio View (BIOV.TA) as of Oct 18, 2026 is -1.94. In the previous year, Altman Z-Score was 0.69 — a change of -382.51% (lower).
Get this data via API
Financial Data API
Altman Z-Score
-1.94
YoY
-382.51%
Last updated:
Altman Z-Score of Bio View is 2025 -1.94 . Altman Z-Score of Bio View was 2024 0.69 . It decreases by -382.51% lower compared to the previous year.
The Bio View Altman Z-Score history
3 Years
10 Years
25 Years
Max
Altman Z-Score
Date
Altman Z-Score
Jan 1, 2018
0.64 ILS
Jan 1, 2019
1.39 ILS
Jan 1, 2020
1.38 ILS
Jan 1, 2021
1.24 ILS
Jan 1, 2022
1.04 ILS
Jan 1, 2023
1.06 ILS
Jan 1, 2024
0.69 ILS
Jan 1, 2025
-1.94 ILS
| YEAR | Altman Z-Score | YoY |
|---|---|---|
| -1.94 | -382.51% | |
| 0.69 | -35.41% | |
| 1.06 | +2.28% | |
| 1.04 | -16.36% | |
| 1.24 | -9.80% | |
| 1.38 | -1.31% | |
| 1.39 | +118.10% | |
| 0.64 | -17.44% | |
| 0.77 | -53.21% | |
| 1.66 | +5.68% | |
| 1.57 | +84.36% | |
| 0.85 | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Bio View Stock analysis
What does Bio View do? Bio View Ltd, based in Rehovot, Israel, operates in the Health Care sector, specializing in the research, development, marketing, and sales of advanced imaging systems. The company manufactures and services the Duet workstation, an automated cell diagnostic system used in cytology, hematology, and pathology laboratories for detecting and analyzing abnormal cells. It also offers the ALLEGRO and ACCORD workstations for specialized applications in cancer diagnosis, minimal-residual disease monitoring, and FISH-based analyses in cytogenetics and oncology. Bio View is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Bio View stock
Altman Z-Score of Bio View is -1.94 in 2025.
On Eulerpool you can find the complete historical development of Altman Z-Score Bio View since 2006 – with annual values, charts, and detailed analysis.
The Altman Z-Score predicts bankruptcy probability using five financial ratios. Scores above 3.0 indicate safety, below 1.8 suggests distress risk.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Quality — Bio View
All Key Metrics — Bio View
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth